Related references
Note: Only part of the references are listed.AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS—2020 UPDATE
Pauline M. Camacho et al.
Endocrine Practice (2020)
Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS)
Chung-Hwan Chen et al.
CLINICAL INTERVENTIONS IN AGING (2020)
Middle East experience from the Asia And Latin America Fracture Observational Study (ALAFOS): Baseline characteristics of postmenopausal women with osteoporosis using teriparatide
Abdul Aziz Elsalmawy et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2020)
Persistence and adherence to parenteral osteoporosis therapies: a systematic review
G. Koller et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies
Stuart Silverman et al.
CALCIFIED TISSUE INTERNATIONAL (2019)
Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)
Chung-Hwan Chen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies
Bente L. Langdahl et al.
BONE (2018)
Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)
Nicola Napoli et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS)
Masayo Sato et al.
ARCHIVES OF OSTEOPOROSIS (2018)
Global dietary calcium intake among adults: a systematic review
E. M. Balk et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Worldwide prevalence and incidence of osteoporotic vertebral fractures
G. Ballane et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS)
Satoshi Soen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Teriparatide for osteoporosis: importance of the full course
R. Lindsay et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Burden of high fracture probability worldwide: secular increases 2010-2040
A. Oden et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study
Osten Ljunggren et al.
BMC MUSCULOSKELETAL DISORDERS (2013)
The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results
S. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2013)
The impact of teriparatide adherence and persistence on fracture outcomes
S. Yu et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Geographic differences in fractures among women
Anna Litwic et al.
WOMENS HEALTH (2012)
Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)
A. Fahrleitner-Pammer et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
R. Lindsay et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
O. Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Quality of life in patients with osteoporosis
P Lips et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
